ENLIVEX THERAPEUTICS LTD's ticker is ENLV and the CUSIP is M4130Y106. A total of 26 filers reported holding ENLIVEX THERAPEUTICS LTD in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $38,236 | -75.6% | 24,200 | -59.5% | 0.00% | – |
| Q2 2023 | $157,011 | -61.5% | 59,700 | -46.6% | 0.00% | – |
| Q1 2023 | $407,316 | -56.8% | 111,900 | -53.7% | 0.00% | – |
| Q4 2022 | $941,850 | -40.4% | 241,500 | -35.0% | 0.00% | – |
| Q3 2022 | $1,580,000 | +150.4% | 371,700 | +166.3% | 0.00% | – |
| Q2 2022 | $631,000 | +22.3% | 139,600 | +51.6% | 0.00% | – |
| Q1 2022 | $516,000 | -56.5% | 92,060 | -51.4% | 0.00% | – |
| Q4 2021 | $1,186,000 | -39.6% | 189,568 | -4.6% | 0.00% | – |
| Q3 2021 | $1,965,000 | +68.2% | 198,800 | +51.4% | 0.00% | – |
| Q2 2021 | $1,168,000 | -62.1% | 131,293 | -52.8% | 0.00% | – |
| Q1 2021 | $3,082,000 | +230.7% | 278,006 | +151.3% | 0.00% | – |
| Q4 2020 | $932,000 | – | 110,622 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACT CAPITAL MANAGEMENT, LLC | 15,000 | $68,000 | 0.10% |
| Susquehanna International Group Ltd. | 22,002 | $98,000 | 0.02% |
| ARK Investment Management | 331,001 | $1,658,000 | 0.01% |
| Compagnie Lombard Odier SCmA | 50,000 | $223,000 | 0.01% |
| EDMOND DE ROTHSCHILD HOLDING S.A. | 13,000 | $59,000 | 0.00% |
| OSAIC HOLDINGS, INC. | 400 | $2,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 1,215 | $5,000 | 0.00% |
| WELLS FARGO & COMPANY/MN | 12,373 | $56,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GROUP ONE TRADING, L.P. | 2,884 | $13,000 | 0.00% |